NEBIVOLOL Drug Patent Profile
✉ Email this page to a colleague
When do Nebivolol patents expire, and when can generic versions of Nebivolol launch?
Nebivolol is a drug marketed by Alkem Labs Ltd, Ani Pharms, Apotex, Aurobindo Pharma Ltd, Cadila Pharms Ltd, Chartwell Rx, Glenmark Pharms Ltd, Hetero Labs Ltd Iii, Indchemie Health, Macleods Pharms Ltd, Mankind Pharma, MSN, Prinston Inc, Regcon Holdings, Reyoung, Torrent, Unichem, and Watson Labs Inc. and is included in eighteen NDAs.
The generic ingredient in NEBIVOLOL is nebivolol hydrochloride. There are fourteen drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the nebivolol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nebivolol
A generic version of NEBIVOLOL was approved as nebivolol hydrochloride by ANI PHARMS on April 16th, 2015.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for NEBIVOLOL?
- What are the global sales for NEBIVOLOL?
- What is Average Wholesale Price for NEBIVOLOL?
Summary for NEBIVOLOL
| US Patents: | 0 |
| Applicants: | 18 |
| NDAs: | 18 |
| Drug Prices: | Drug price information for NEBIVOLOL |
| DailyMed Link: | NEBIVOLOL at DailyMed |
US Patents and Regulatory Information for NEBIVOLOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mankind Pharma | NEBIVOLOL HYDROCHLORIDE | nebivolol hydrochloride | TABLET;ORAL | 216172-003 | Nov 14, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Indchemie Health | NEBIVOLOL HYDROCHLORIDE | nebivolol hydrochloride | TABLET;ORAL | 203828-002 | Jul 29, 2015 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Prinston Inc | NEBIVOLOL HYDROCHLORIDE | nebivolol hydrochloride | TABLET;ORAL | 212682-003 | Apr 7, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
